Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Attovia Therapeutics, Inc.NASDAQ: ATTO

Operating Income · Q2 FY2026 · quarter ended Jun 2026

Operating income of -$21.8M in Q2 FY2026

Q2 FY2026 operating income was -$21.8M.

Context

  • Operating income amounted to 4974.7% of revenue in FY2025.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$21.8M-9.3% QoQ
Last fiscal yearDec 2025
-$67.16M-61.6% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-61.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Operating Income history

USD · from the income statement

Latest · FY2025
(67.16M) USD
Year-over-year change
-61.6%

Operating Income vs competitors

How ATTO compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -61.6% is the 9th highest of 10, against a peer median of -23.4%.
  • Operating income amounts to 4974.7% of revenue for ATTO, versus a peer median of 930.9%.
ATTO Competitors
Operating Income for ATTO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANABAnaptysBio, Inc.LTM Mar 2026$40.8M USD+140.7%—17.6%
QTTBQ32 Bio Inc.LTM Mar 2026$21.41M USD+133.7%—39.8%
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024-€48.02M EUR-54.0%——
CNTBConnect Biopharma Holdings LimitedFY2025-$58.07M USD-158.7%—90740.6%
ATTOAttovia Therapeutics, Inc.FY2025-$67.16M USD-61.6%—4974.7%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-$80.48M USD+43.0%—961.9%
ZURAZura Bio LimitedLTM Mar 2026-$81.49M USD-23.4%——
EVMNEvommune, Inc.LTM Mar 2026-$89.99M USD——899.9%
ORKAOruka Therapeutics, Inc.LTM Sep 2026-$183.11M USD-45.4%——
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026-$267.37M USD-56.6%——
ALMSAlumis Inc. Common StockLTM Jun 2026-$459M USD-4.5%—6204.4%
Peer median (excluding ATTO) —-23.4%—930.9%

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2024
Dec 2024
FY2025
Dec 2025
Revenue01.35M
Cost of Revenue313K804K
Gross Profit(313K)546K
Gross Margin—40.4%
Research & Development33.86M54.15M
Selling, General & Admin7.38M13.55M
Operating Expenses41.24M67.71M
Depreciation & Amortization313K804K
EBITDA(41.24M)(66.36M)
EBITDA Margin—-4915.2%
Operating Income(41.55M)(67.16M)
Operating Margin—-4974.7%
Interest Income3.44M6.63M
Interest Expense00
Other Income / Expenses1.75M6.53M
Income Before Tax(39.8M)(60.63M)
Pre-Tax Margin—-4490.9%
Income Tax Expense00
Net Income(39.8M)(60.63M)
Net Margin—-4490.9%
EPS (Basic)(1.05)(1.42)
EPS (Diluted)(1.05)(1.42)
Weighted Avg Shares43.03M43.03M
Weighted Avg Shares (Diluted)43.03M43.03M

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.